Acute myeloid leukemia trials in France

In France 87 Also abroad 761

87 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 2Enrolling by invitation
RVU120 Rollover Study
Where
Nice, Pessac
Age
18 years and over
People
14 worldwide
Run by
Ryvu Therapeutics SA
See details and how to joinNCT06987058 · EU 2025-521673-14-00
Phase 2Not yet taking people in France
FILO-AML-01-MIVONU A single arm phase II study investigating the efficacy and safety of the addition of ivosidenib to oral azacitidine (Onureg®) in patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation, in complete remission after intensive chemotherapy. A study of the French AML Intergroup.
Where
ANGERS Cedex 09, Bayonne, Besançon Cedex, Clamart, Créteil Cedex, Grenoble Cedex 9, Lille, Limoges Cedex, Nantes, Nimes Cedex 9, Paris, Perpignan Cedex, Pessac, Pierre-Bénite, Rennes, Rouen, Toulouse Cedex 9, Tours Cedex 9, Vandoeuvre Les Nancy, Villejuif Cedex
Age
18 years and over
People
60
Run by
French Innovative Leukemia Organization
See details and how to join2025-521322-14-00 · EU 2025-521322-14-00
Phase 2Taking people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Where
Paris, Poitiers, Toulouse
Age
18 years and over
People
140 worldwide
Run by
Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00
Phase 1/2Taking people
A Study of BGB-11417 in Participants With Myeloid Malignancies
Where
Lille Cedex, Nice, Paris
Age
18 years and over
People
260 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00
No phaseTaking people
Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia
Where
Rouen
Age
18 years and over
People
6,990
Run by
Groupe Francophone des Myelodysplasies
See details and how to joinNCT06956755
No phaseTaking people
Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy
Where
Nantes
Age
18 years to 99 years
People
60
Run by
Nantes University Hospital
See details and how to joinNCT06439199
Phase 3Taking people
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Where
Amiens Cedex 1, Angers, Besancon Cedex, Caen Cedex 9, Clamart, Clermont-Ferrand, Creteil Cedex, Grenoble Cedex 9, Le Chesnay Rocquencourt, Lille Cedex, Limoges Cedex 1, Metz Cedex 03, Montpellier Cedex 5, Nantes, Nice, Pessac, Pierre-Bénite, Rouen Cedex, Saint-Priest-en-Jarez, Strasbourg Cedex 2
Age
18 years and over
People
448 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT06652438 · EU 2024-512733-32-00
Phase 1/2Taking people
Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)
Where
Paris, Pessac, Toulouse, Villejuif
Age
18 years to 66 years
People
10
Run by
Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT04707300
Phase 2/3Taking people
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Where
ANGERS Cedex 09, Grenoble, Paris, Strasbourg
Age
18 years to 80 years
People
312 worldwide
Run by
Moleculin Biotech, Inc.
See details and how to joinNCT06788756 · EU 2024-518359-47-00
Phase 2Enrolling by invitation
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Where
Mulhouse
Age
18 years and over
People
332 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04093570 · EU 2024-516293-29-01
Phase 1/2Not yet taking people in France
Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia
Where
Bayonne, Pessac, Toulouse
Age
18 years to 70 years
People
41
Run by
University Hospital, Bordeaux
See details and how to joinNCT07726576
Phase 1Taking people
A Study to Assess Adverse Events and How Pivekimab Sunirine Moves Through the Body of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Where
Bordeaux, Paris
Age
Up to 17 years
People
18 worldwide
Run by
AbbVie Deutschland GmbH & Co. KG
See details and how to join2024-520125-36-00 · EU 2024-520125-36-00
Phase 1/2Not yet taking people in France
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
Where
Marseille, Nice, Paris, Pessac Cedex, Villejuif
Age
18 years and over
People
64 worldwide
Run by
Servier
See details and how to joinNCT07719348 · EU 2025-525128-88-00
Phase 2/3Taking people
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
Where
Amiens Cedex 1, Angers, Argenteuil Cedex, Avignon Cedex 9, Bayonne, Besançon, Béziers, Bobigny, Boulogne-sur-Mer, Brest Cedex 2, Caen Cedex 9, Clamart, Clermont-Ferrand, Colmar Cedex, Corbeil Essonnes Cedex, Creteil Cedex, Dijon, Dunkirk Cedex 1, Grenoble Cedex 9, Le Chesnay Rocquencourt, Lens, Lille Cedex, Limoges Cedex 1, Lyon, Marseille, Meaux, Metz Cedex 03, Montpellier Cedex 5, Mulhouse, Nantes, Nice, Nice Cedex 2, Nimes Cedex 9, Orleans Cedex 2, Paris, Perpignan Cedex, Pessac, Pierre-Bénite, Poitiers, Pontoise, Reims Cedex, Rennes, Roubaix, Rouen Cedex, Saint-Cloud, Saint-Denis, Saint-Priest-en-Jarez, Strasbourg Cedex 2, Toulouse Cedex 9, Tours Cedex 9, Valenciennes, Vandoeuvre Les Nancy, Villejuif
Age
18 years to 61 years
People
3,100
Run by
University Hospital, Angers
See details and how to joinNCT02416388 · EU 2024-516873-57-00
Phase 3Taking people
Study comparing thymoglobulin to grafalon, two treatments used to prevent graft versus host disease in elderly patients with acute myeloid leukemia or myelodysplastic syndrome and receiving an allogeneic stem cell transplantation with an unrelated matched donor after a reduced intensity conditioning regimen
Where
Amiens Cedex 1, Angers, Besancon Cedex, Brest Cedex 2, Caen Cedex 9, Clermont-Ferrand, Creteil Cedex, Grenoble Cedex 9, Lille, Limoges, Marseille, Montpellier Cedex 5, Nantes, Nice, Paris, Pessac, Pierre-Bénite, Poitiers, Rennes, Saint-Priest-en-Jarez, Strasbourg Cedex 2, Toulouse Cedex 9, Tours Cedex 9, Vandoeuvre Les Nancy, Villejuif
Age
18 years and over
People
334 worldwide
Run by
Assistance Publique Hopitaux De Paris
See details and how to join2023-504555-27-00 · EU 2023-504555-27-00
Phase 3Taking people
FLUCLORIC - Randomized multicentric Phase III study comparing the efficacy of two reduced intensity conditioning regimens (clofarabine/busulfan versus fludarabine/busulfan) in adults with acute myeloid leukemia and eligible to allogeneic stem cell transplantation: a SFGM-TC study
Where
Amiens, Angers Cedex 9, Besancon Cedex, Brest, Caen Cedex 9, Clermont-Ferrand, Creteil Cedex, Grenoble Cedex 9, Lille Cedex, Limoges Cedex 1, Marseille, Montpellier Cedex 5, Nantes Cedex 1, Paris, Paris Cedex 12, Paris Cedex 13, Pessac, Pierre-Bénite, Poitiers, Rennes Cedex 9, Saint-Priest-en-Jarez, Toulouse Cedex 9, Vandoeuvre Les Nancy
Age
18 years and over
People
302
Run by
Centre Hospitalier Universitaire De Nantes
See details and how to join2022-502019-12-00 · EU 2022-502019-12-00
No phaseTaking people
Biocollection in MyeloDysplastic Syndrome (P-MDS)
Where
Brest
Age
18 years and over
People
150
Run by
University Hospital, Brest
See details and how to joinNCT04869683
Phase 1Taking people
Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)
Where
Nantes
Age
60 years and over
People
12
Run by
Nantes University Hospital
See details and how to joinNCT05749276
Phase 1/2Taking people
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Where
Bordeaux, Villejuif
Age
18 years and over
People
250 worldwide
Run by
CellCentric Ltd.
See details and how to joinNCT04068597
No phaseNot yet taking people in France
Study of NK Cells in the Monitoring of Patients With Acute Leukemia or Myelodysplasia
Where
Nantes
Age
18 years and over
People
55
Run by
Nantes University Hospital
See details and how to joinNCT07249476
Phase 1Taking people
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Where
Marseille, Pessac, Pierre-Bénite, Villejuif
Age
18 years and over
People
291 worldwide
Run by
Institut de Recherches Internationales Servier
See details and how to joinNCT02074839
Phase 1/2Not yet taking people in France
ACTIVATE - Phase 1 Clinical Trial evaluating the combination of Actinomycin D and venetoclax in patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Where
Bobigny, Marseille, Nice, Paris, Villejuif Cedex
Age
18 years and over
People
36
Run by
Assistance Publique Hopitaux De Paris
See details and how to join2025-524728-22-01 · EU 2025-524728-22-01
No phaseTaking people
Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelodysplastic Syndrome (MDS) Monitored at the Nantes University Hospital
Where
Nantes
Age
18 years and over
People
1,000
Run by
Nantes University Hospital
See details and how to joinNCT06681363
Phase 1/2Not yet taking people in France
Phase 1/2 evaluating the addition of venetoclax to standard 3+7 and midostaurin induction treatment in patients with FLT3-mutated Acute Myeloid Leukemia eligible to intensive chemotherapy - MIDOVEN
Where
Bayonne, Pessac, Toulouse Cedex 9
Age
18 years and over
People
41
Run by
Centre Hospitalier Universitaire De Bordeaux
See details and how to join2024-517130-17-00 · EU 2024-517130-17-00
Phase 3Taking people
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
Where
Angers Cedex 9, Caen Cedex 9, Clamart, Clermont-Ferrand, Grenoble Cedex 9, Lille Cedex, Limoges Cedex 1, Marseille, Nice, Orleans Cedex 2, Pessac, Pierre-Bénite, Rennes Cedex 9, Toulouse Cedex 9
Age
18 years and over
People
245 worldwide
Run by
Servier Affaires Médicales
See details and how to joinNCT05907057 · EU 2022-501709-11-00